Aripiprazole Ingestion in Two Pediatric Patients

Aripiprazole Ingestion in Two Pediatric Patients

Aripiprazole (Abilify registered ) is an atypical neuroleptic drug approved in November 2002 for the treatment of schizophrenia. Usual adult doses are 10 to 15 mg daily. Its exact mechanism of action is unknown but is believed to involve partial agonist effects on dopamine D2 and serotonin 5-HT1A re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of toxicology. Clinical toxicology 2004-08, Vol.42 (5), p.738-738
Hauptverfasser: Roche, K, Clark, R, Sangalli, B, McKay, CA, Bayer, MJ
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aripiprazole (Abilify registered ) is an atypical neuroleptic drug approved in November 2002 for the treatment of schizophrenia. Usual adult doses are 10 to 15 mg daily. Its exact mechanism of action is unknown but is believed to involve partial agonist effects on dopamine D2 and serotonin 5-HT1A receptors and antagonism of 5-HT2A receptors. Data are limited as to its effects in overdose and in accidental pediatric ingestions. We report two pediatric cases involving aripiprazole ingestion.
ISSN:0731-3810